Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.58 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.58 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.58 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7733701 | 0.89 | L3MBTL1 (1.00) | L3MBTL1ALDH1A1LMNAALOX12MAPT | |
| SCHEMBL28307531 | 0.84 | ALDH1A1 (0.57) | L3MBTL1ALDH1A1LMNAALOX12MAPT | |
| SCHEMBL20216834 | 0.82 | MEN1 (0.54) | L3MBTL1ALDH1A1LMNAALOX12MAPT | |
| SCHEMBL26361794 | 0.81 | HTT (0.61) | L3MBTL1ALDH1A1LMNAALOX12MAPT | |
| SCHEMBL22962867 | 0.81 | GAA (0.55) | L3MBTL1ALDH1A1LMNAALOX12MAPT | |
| SCHEMBL4110532 | 0.81 | L3MBTL1 (0.83) | L3MBTL1ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL1422823 | 0.81 | L3MBTL1 (0.83) | L3MBTL1ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL8777217 | 0.81 | L3MBTL1 (0.83) | L3MBTL1ALDH1A1LMNAALOX12MAPT | |
| SCHEMBL18033762 | 0.81 | L3MBTL1 (0.83) | L3MBTL1ALDH1A1LMNAALOX12MAPT | |
| SCHEMBL5549558 | 0.81 | CA12 (0.59) | L3MBTL1ALDH1A1LMNAALOX12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954705-A | Indole derivative and preparation method thereof | 南阳师范学院 | 2025-05-09 | — | — | CN | claimed |
| CN-119954705-A | Indole derivative and preparation method thereof | 南阳师范学院 | 2025-05-09 | — | — | CN | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11771677-B2 | Immunomodulating urea azalides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| CN-113912529-B | Method for synthesizing indole compounds by catalyzing N-aryl amide compounds and vinylene carbonate with ruthenium | 成都大学 | 2023-07-25 | — | — | CN | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| CN-113416139-B | 4-fluorine substituted aryl amine compound and synthetic method thereof | 江苏笃行致远新材料科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-113912529-A | Method for synthesizing indole compound by catalyzing N-aryl amide compound and vinylene carbonate with ruthenium | 成都大学 | 2022-01-11 | — | — | CN | disclosed |
| US-11220506-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors | BEIGENE, LTD. (KY) | 2022-01-11 | — | — | US | disclosed |
| US-20210290591-A1 | IMMUNOMODULATING UREA AZALIDES | ZOETIS SERVICES LLC | 2021-09-23 | — | — | US | disclosed |
| EP-1091944-A1 | 1,3-BENZODIAZEPIN-2-ONES AND 1,3-BENZOXAZEPIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001025229-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| US-6204262-B1 | 1,3-Benzodiazepin-2-ones and 1,3-Benzoxazepin-2-ones useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2001-03-20 | — | — | US | disclosed |
| US-6140320-A | FOR TREATING HIV(HUMAN IMMUNODEFICIENCY VIRUS) INFECTIONS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1009742-A1 | 5,5-DISUBSTITUTED-1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-06-21 | — | — | EP | disclosed |
| US-6040480-A | PREPARING 2-(1,1,1-TRIFLUORO-2-HYDROXY-4-CYCLOPROPYL-BUT-3-YN-2-YL),4-CHLOROANILINE; CYCLIZATION; HUMAN IMMUNODEFICIENCY VIRUS (HIV) REVERSE TRANSCRIPTASE INHIBITOR NONTOXIC MAATERIALS; NONCHROMAGRAPHIC PURIFICATION | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| WO-2000000479-A1 | 1,3-BENZODIAZEPIN-2-ONES AND 1,3-BENZOXAZEPIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5932726-A | VIRICIDE, ENZYME INHIBITOR; 6-CHLORO-4-CYCLOPROPYLETHYNYL4-TRIFLUOROMETHYL-1,4-DIHYDRO2H-3 ,1-BENZOXAZIN-2-ONE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5925789-A | MULTISTAGE PROCESS WITH AMINATION, DEHYDRATION AND STIRRING TO GIVE AN INTERMEDIATE IN THE SYNTHESIS OF 6-CHLORO-4-CYCLO PROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-2H-3,1-BENZOXAZINE-2-ONE AS AN INHIBITOR OF HIV REVERSE TRANSCRIPTASE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1999011635-A1 | 5,5-DISUBSTITUTED-1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | L3MBTL1 1901/4885ALDH1A1 3253/4885LMNA 738/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | L3MBTL1 1142/4885ALDH1A1 3689/4885LMNA 326/4885 |
| US-11771677-B2 | Immunomodulating urea azalides | ARG1, IL2, CD209 | L3MBTL1 1830/4885ALDH1A1 371/4885LMNA 4881/4885 |
| US-20210290591-A1 | IMMUNOMODULATING UREA AZALIDES | ARG1, IL2, CD209 | L3MBTL1 1830/4885ALDH1A1 371/4885LMNA 4881/4885 |
| US-11220506-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors | PIK3CD, PIK3R5, PIK3CA | L3MBTL1 3962/4885ALDH1A1 2121/4885LMNA 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.